News
The most recent news and industry headlines are presented in this section. Our dedicated team closely observes the pharmaceutical industry and keeps you informed of the most recent developments around the Europe.
QuANTUM-Wild Phase 3 Trial of VANFLYTA® Initiated in Patients with Newly Diagnosed FLT3-ITD Negative AML
Wednesday, December 11, 2024The first patient has been dosed in the QuANTUMWild phase trial evaluating Daiichi Sankyos VANFLYTA quizartinib in combination with standard intensive induction and consolidation chemotherapy followed by singleagent maintenance in adults with newly...
Eikonizo Therapeutics Announces Investment by Novo Nordisk; Advancing Lead Candidate EKZ-102 Toward Clinical Development
Wednesday, December 11, 2024Eikonizo Therapeutics a biopharmaceutical company dedicated to developing diseasemodifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases announced today that it has secured an undisclosed equity inves...
Mestag Therapeutics Announces Licensing of a Novel Inflammatory Disease Target from its RAFT Platform
Tuesday, December 10, 2024Mestag Therapeutics a biotech company harnessing new insights into fibroblastimmune interactions today announced that Johnson Johnson has exclusively licensed a novel undisclosed target identified using Mestags Reversing Activated Fibroblast Technol...
NANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
Tuesday, December 10, 2024NANOBIOTIX a lateclinical stage biotechnology company pioneering nanoparticlebased therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases today announced the completion of the dose escalation and do...
Immunovia announces positive outcome and strong accuracy in the clinical validation of its next-generation test for pancreatic cancer
Monday, December 09, 2024Immunovia the pancreatic cancer diagnostics company today announces the successful completion of the CLARITI study Clinical Validation of NextGeneration Test for EarlyStage Pancreatic Cancer to detect earlystage pancreatic ductal adenocarcinoma PDAC
Vivoryon Therapeutics N.V. Presents Topline Phase 2 Data from VIVA-MIND Strongly Supporting Varoglutamstat’s Potential to Improve Kidney Function
Monday, December 09, 2024Vivoryon Therapeutics NV a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins today announced positive Phase topline data from its US...
Medigene AG Announces KRAS G12V as First Target for TCR-guided T Cell Engagers
Monday, December 09, 2024Medigene AG an oncology platform company focused on the research and development of T cell receptor TCRguided therapies for the treatment of cancer today announced the selection of Kirsten rat sarcoma viral oncogene homologue
Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan
Friday, December 06, 2024Teva Pharmaceutical Industries Ltd announced that it has entered into an agreement with JKI established by the fund managed and operated by JWill whereby all shares of Teva Takeda Pharma Limited and its wholly owned subsidiary Teva Takeda Yakuhin Ltd...
Saol Therapeutics Announces Submission of New Drug Application (NDA) to the U.S. FDA for SL1009
Wednesday, December 04, 2024Saol Therapeutics a privately held clinicalstage pharmaceutical company today announced the submission of a New Drug Application NDA to the US Food and Drug Administration FDA for approval of SL Sodium Dichloroacetate Oral Solution DCA for use with a...
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous
Wednesday, December 04, 2024Merck known as MSD outside of the United States and Canada today announced that the US Food and Drug Administration FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan sacTMT for the treatment of patients with advanced or meta...
